SAN DIEGO, Nov. 1 (UPI) -- TargeGen said Wednesday it has begun a phase 1 trial of its topical drug to treat age-related macular degeneration (AMD).
The company said a single-site, 45-patient study will test its small-molecule, multi-tageted kinase inhibitor TG100801 as a therapy for AMD and other eye diseases.
The drug, applied daily as an eye drop, suppresses disease-related edema, angiogenesis and inflammation. TargeGen said it expects to complete the phase 1 study by the end of the first quarter 2007 and start a phase 2 trial by mid-year.
Macular degeneration is the leading cause of blindness in adults, the company said.